- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03895346
Mental Training for Adults With Mild Cognitive Impairment
September 14, 2022 updated by: Sara W Lazar, Massachusetts General Hospital
This study aims to determine the feasibility and acceptability of conducting a larger randomized clinical trial to test whether individuals with MCI can benefit from mental training programs.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Half of participants will be randomized to a mindfulness group and half to a brain games and puzzles group as forms of mental training.
Participants are adults with mild cognitive impairment.
Participants will undergo neuropsychological testing, MRI scanning, and qualitative interviews to assess feasibility of conducting a larger randomized clinical trial in a population with mild cognitive impairment.
Study Type
Interventional
Enrollment (Actual)
22
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02119
- Massachusetts General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 90 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- CDR (clinical dementia rating) of 0.5
- 50-90 years of age
- Able to speak, read, and understand English
- Willing to participate in a 6 month study and undergo 2 MRI scans at Mass General Hospital
- A score suggesting Mild Cognitive Impairment on the Telephone Interview for Cognitive Status (TICS)
- A Mini Mental State Exam adjusted for age and education of 24 to 30
- Stable medications for at least 30 days
- Subjects with well-controlled vascular risk factors such as treated hypertension, treated hyperlipidemia or well-controlled Type II diabetes (glucose levels < 250) will be included.
- Subjects with a history of cerebrovascular problems but have no persistent neurological deficits will be included
- Available for scheduled class times for both study courses
- Able to complete 40 minutes of homework per day during the 6-month course
- CDR (clinical dementia rating) of 0.5
Exclusion Criteria:
- CDR score other than 0.5
- Cardiovascular disease, stroke, congestive heart failure
- Has surgical aneurysm clips, neurostimulator, implanted pumps, metal fragments in eyes, cardiac pacemaker, non-removable nitroglycerin patch, non-MRI compatible cochlear implants, any other non-MRI compatible metal in body
- Has permanent bridgework in upper mouth that could interfere with MRI scan
- Active hematological, renal, pulmonary, endocrine, or hepatic disorders
- Uncontrolled high blood pressure
- Uncontrolled diabetes or insulin-treated diabetes (diabetes that is controlled with no more than one oral medication will be allowed)
- A history of neurological disease or injury, including a history of seizures or significant head trauma (i.e. extended loss of consciousness, bleeding in the brain, Parkinson's disease, stroke)
- Received treatment for cancer within the last year (skin cancer will be allowed as will any cancer more than 2 years since the last treatment)
- Diagnosis of schizophrenia, PTSD, bipolar disorder, or psychotic disorder at any point during lifetime
- Any axis I psychiatric disorder within the last 12 months
- Weighs more than 350 pounds
- Neurological or medical conditions that would interfere with study procedures or confound results, such as conditions that alter cerebral blood flow or metabolism
- Unstable medications or on medications with CNS effects including cholinesterase inhibitors, memantine, and antidepressants
- Use of psychotropic medications within 12 months prior to the study
- Daily use of any medication that alters neural metabolism or blood flow, including chronic use of benzodiazepines, potent CNS penetrant anticholinergic medications (for bladder control or allergies). These medications taken on an as-needed basis (prn) will be allowed. (Over the counter supplements such as Gingko and fish oil will be allowed)
- Any other medications as reviewed by a clinician on a case-by-case basis
- Current regular practice of meditation, yoga, tai chi, Feldenkrais, or other mind-body practice or more than 8 30-minute long mind-body sessions within the last 6 months. Significant prior mind-body experience as determined by the PI based on frequency, duration, recency, and type of practice.
- Claustrophobia
- Any other criteria that will interfere with the subject's participation as determined by study doctor
- Participation in any investigational drug study within 4 weeks of screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Mindfulness
Class meeting three times a week for six months, led by a certified mindfulness meditation instructor.
Includes instruction and practice on techniques such as breathing, body scan, physical sensations, and yoga.
|
Mindfulness meditation is a technique of sustained attention and focus, involving preventing the mind from wandering from the meditative object (i.e.
breath or body sensations)
Other Names:
|
ACTIVE_COMPARATOR: Brain Games and Puzzles
Class meeting three times a week for six months, led by a qualified instructor.
Includes teaching and practice of puzzles such as word searches, crossword puzzles, Sudoku, and KenKen.
|
Intervention will include the instruction and practice of puzzles such as word searches, crossword puzzles, Sudoku, and KenKen.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recruitment feasibility
Time Frame: 6 months
|
Number of subjects recruited within 6 months; determine the number of people excluded for each inclusion/exclusion criterion; assessing reasons why eligible people decide not to enroll.
|
6 months
|
Retention
Time Frame: 6 months
|
Remaining in the study for the full duration of all testing time points (yes/no).
Quantify the reasons for dropout
|
6 months
|
Adherence to study protocol
Time Frame: 6 months
|
Number of classes attended; number of times the subject practiced prescribed activities at home; number of people who complete each test/assessment.
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
April 10, 2019
Primary Completion (ACTUAL)
March 30, 2020
Study Completion (ACTUAL)
December 31, 2021
Study Registration Dates
First Submitted
March 26, 2019
First Submitted That Met QC Criteria
March 27, 2019
First Posted (ACTUAL)
March 29, 2019
Study Record Updates
Last Update Posted (ACTUAL)
September 15, 2022
Last Update Submitted That Met QC Criteria
September 14, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018P002574
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aging
-
Tuba MadenCompletedAging | Aging Problems | Aging Disorder
-
Radboud University Medical CenterNot yet recruitingAging | Aging Well | Immuno Aging
-
University of Santiago de CompostelaEuropean Regional Development Fund; Center for Industrial Technological Development...Completed
-
TruDiagnosticBlushield USANot yet recruitingAging | Aging Well
-
San Diego State UniversityCompleted
-
Lithuanian Sports UniversityCompletedAging | Healthy AgingLithuania
-
Amazentis SAproDERM GmbHCompleted
-
Northumbria UniversityUniversity of East AngliaSuspendedSleep | Aging | Healthy AgingUnited Kingdom
-
University of West AtticaNot yet recruiting
-
University of Santiago de CompostelaAgencia Estatal de Investigación, SpainRecruiting
Clinical Trials on Mindfulness
-
University of Illinois at Urbana-ChampaignNorthwestern University Feinberg School of Medicine; Southern Illinois University and other collaboratorsNot yet recruitingPain, Postoperative | Depression, Unipolar
-
University of HoustonCompletedDepression | Stress | Anxiety | Well-beingUnited States
-
University of HawaiiVA Palo Alto Health Care SystemCompletedCancer, Other Than Non-melanoma Skin CancerUnited States
-
Monash University MalaysiaCompleted
-
Oregon Health and Science UniversityPortland VA Medical CenterCompleted
-
Lund UniversityCompleted
-
University of UlsterRecruitingCervical Cancer | Gynecologic Cancer | Vulvar Cancer | Vaginal Cancer | Uterus Cancer | Ovary CancerUnited Kingdom
-
Sam Houston State UniversityTerminated